Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
41.06
-0.49 (-1.18%)
Apr 9, 2026, 3:00 PM CST
SHA:600329 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,016 | 2,944 | 2,125 | 2,883 | 2,283 |
Short-Term Investments | - | 1,000 | 61.7 | 40.61 | 109.64 |
Cash & Short-Term Investments | 1,016 | 3,945 | 2,187 | 2,923 | 2,393 |
Cash Growth | -74.23% | 80.37% | -25.19% | 22.16% | 20.40% |
Accounts Receivable | 1,571 | 1,316 | 2,653 | 2,725 | 1,971 |
Other Receivables | 9.43 | 8.56 | 34.1 | 60.77 | 40.73 |
Receivables | 1,581 | 1,325 | 2,687 | 2,785 | 2,011 |
Inventory | 1,133 | 1,286 | 1,567 | 1,429 | 1,525 |
Other Current Assets | 3,424 | 52.96 | 111.07 | 107.5 | 495.77 |
Total Current Assets | 7,155 | 6,608 | 6,552 | 7,245 | 6,425 |
Property, Plant & Equipment | 1,142 | 1,393 | 1,442 | 1,465 | 1,486 |
Long-Term Investments | 1,166 | 1,294 | 882.67 | 801.46 | 740.74 |
Goodwill | - | 12.3 | 65.91 | 84.69 | - |
Other Intangible Assets | 292.75 | 295.29 | 317.75 | 281.13 | 198.19 |
Long-Term Deferred Tax Assets | 341.01 | 314.4 | 265.99 | 208.35 | 154.6 |
Long-Term Deferred Charges | 52.83 | 66.07 | 18.3 | 17.54 | 4.72 |
Other Long-Term Assets | 1,541 | 785.43 | 686.29 | 53.77 | 57.51 |
Total Assets | 11,690 | 10,769 | 10,230 | 10,157 | 9,067 |
Accounts Payable | 218.05 | 284.51 | 1,126 | 1,406 | 1,242 |
Accrued Expenses | 225.05 | 1,787 | 1,493 | 1,170 | 679.77 |
Short-Term Debt | 57.9 | 21.65 | 81.8 | 101.64 | - |
Current Portion of Long-Term Debt | 3.12 | - | - | - | 30 |
Current Portion of Leases | - | 1.33 | 3.56 | 4.1 | 1.6 |
Current Income Taxes Payable | 115.93 | 297.57 | 76.68 | 93.28 | 9.53 |
Current Unearned Revenue | 148.53 | 123.14 | 145.66 | 219.07 | 215.61 |
Other Current Liabilities | 3,738 | 302.52 | 305.66 | 339.37 | 254.89 |
Total Current Liabilities | 4,506 | 2,818 | 3,233 | 3,333 | 2,434 |
Long-Term Debt | - | 10 | 251.03 | 161.3 | 10 |
Long-Term Leases | 4.66 | 5.6 | 2.74 | 0.87 | 1.57 |
Long-Term Unearned Revenue | 45.49 | 55.14 | 57.14 | 59.88 | 59.15 |
Long-Term Deferred Tax Liabilities | 0.28 | 6.04 | 7.33 | 8.82 | 4.21 |
Other Long-Term Liabilities | 32.93 | 24.07 | 33.69 | 40.73 | 44.42 |
Total Liabilities | 4,590 | 2,919 | 3,585 | 3,605 | 2,553 |
Common Stock | 770.09 | 770.09 | 770.16 | 773.44 | 773.44 |
Additional Paid-In Capital | 974.98 | 974.79 | 975.21 | 1,048 | 1,374 |
Retained Earnings | 5,330 | 6,072 | 4,828 | 4,700 | 4,218 |
Treasury Stock | - | - | -7.04 | -29.75 | -32.03 |
Comprehensive Income & Other | 24.07 | 26.93 | 34.34 | 29.53 | 30.62 |
Total Common Equity | 7,099 | 7,844 | 6,601 | 6,521 | 6,364 |
Minority Interest | 0.45 | 6.34 | 44.55 | 30.49 | 149.35 |
Shareholders' Equity | 7,100 | 7,850 | 6,645 | 6,552 | 6,514 |
Total Liabilities & Equity | 11,690 | 10,769 | 10,230 | 10,157 | 9,067 |
Total Debt | 65.68 | 38.59 | 339.14 | 267.91 | 43.17 |
Net Cash (Debt) | 950.74 | 3,906 | 1,848 | 2,655 | 2,350 |
Net Cash Growth | -75.66% | 111.39% | -30.41% | 13.01% | 20.83% |
Net Cash Per Share | 1.24 | 5.06 | 2.40 | 3.42 | 3.05 |
Filing Date Shares Outstanding | 771.38 | 770.09 | 770.16 | 773.44 | 773.44 |
Total Common Shares Outstanding | 771.38 | 770.09 | 770.16 | 773.44 | 773.44 |
Working Capital | 2,648 | 3,790 | 3,319 | 3,912 | 3,991 |
Book Value Per Share | 9.20 | 10.19 | 8.57 | 8.43 | 8.23 |
Tangible Book Value | 6,807 | 7,536 | 6,217 | 6,156 | 6,166 |
Tangible Book Value Per Share | 8.82 | 9.79 | 8.07 | 7.96 | 7.97 |
Buildings | - | 1,325 | 1,338 | 1,337 | 1,323 |
Machinery | - | 1,066 | 1,107 | 1,087 | 1,028 |
Construction In Progress | - | 436.35 | 386.46 | 333.85 | 331.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.